Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

190.56 -1.35 (-0.70%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

59 60 Next >

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

April 15, 2025

From Biogen Inc.

Via GlobeNewswire

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. ↗

April 10, 2025

From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.

Via Investor's Business Daily

Topics Government

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

How Is The Market Feeling About Biogen? ↗

March 07, 2025

Via Benzinga

Biogen Analysts Lower Their Forecasts After Q4 Results ↗

February 13, 2025

Via Benzinga

Forecasting The Future: 10 Analyst Projections For Biogen ↗

February 13, 2025

Via Benzinga

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

What 14 Analyst Ratings Have To Say About Biogen ↗

April 04, 2025

Via Benzinga

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

April 02, 2025

From Biogen Inc.

Via GlobeNewswire

European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen ↗

March 28, 2025

Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.

Via Benzinga

Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 ↗

March 27, 2025

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.

Via The Motley Fool

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

March 24, 2025

From Biogen Inc.

Via GlobeNewswire

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

March 11, 2025

From Biogen Inc.

Via GlobeNewswire

Indexes Swimming In Red Ink On Recession Fears ↗

March 10, 2025

Stocks are looking to extend last week's losses, as recession fears grip Wall Street.

Via Talk Markets

Topics Economy Stocks / Equities

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding ↗

March 06, 2025

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,...

Via Benzinga

Stocks Plummet As Trade Partners Retaliate Against Tariffs ↗

March 04, 2025

Stocks are free falling as President Donald Trump's tariffs against Mexico, Canada, and China take effect.

Via Talk Markets

Topics Government Stocks / Equities World Trade

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

March 03, 2025

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and...

Via StockStory

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

Biogen Stock Is Mutating Into a Value Play

February 20, 2025

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Via MarketBeat

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗

February 18, 2025

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Via Benzinga

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

February 18, 2025

From Biogen Inc.

Via GlobeNewswire

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts ↗

February 13, 2025

Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Via Benzinga

Top S&P500 movers in Wednesday's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook ↗

February 12, 2025

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.